Employees: 3,514
Size Lushang Freda Pharmaceutical (600223.SS) is a China Real Estate company (Real Estate Development) with a market value of $781M, the 2642nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥5.16 on 18 Nov 2026.
Performance Over six months the shares fell 19.5%, against -15.8% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 1.9% over the last twelve months (peer median -1.5%); the operating margin is 3.9% (peer median 6.2%).
Valuation It trades at 28.4× forward earnings against a peer median of 11.4× (4th most expensive of 8).
Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.83B | CN¥3.63B | CN¥3.96B | CN¥4.55B | CN¥12.9B |
| Revenue growth | — | -8% | -13% | -65% | — |
| Gross profit | CN¥2.20B | CN¥1.85B | CN¥2.02B | CN¥2.05B | CN¥3.04B |
| EBITDA | n/a | CN¥295M | CN¥325M | CN¥383M | CN¥658M |
| Net income | CN¥157M | CN¥188M | CN¥244M | CN¥303M | CN¥45.5M |
| Free cash flow | CN¥225M | CN¥228M | CN¥227M | CN¥325M | CN¥963M |
| Capital expenditure | CN¥99.2M | CN¥110M | CN¥157M | CN¥211M | CN¥166M |
| Total debt | CN¥88.9M | CN¥149M | CN¥300M | CN¥2.18B | CN¥9.45B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600223.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.0% | -6.0% | 8th lowest of 21 |
| 6-month return | -19.5% | -15.8% | 9th lowest of 20 |
| Distance from 52-week high | -38.4% | -36.2% | 10th lowest of 21 |
| Revenue growth (TTM) | +1.9% | -1.5% | 9th highest of 21 |
| Operating margin | 3.9% | 6.2% | 10th lowest of 21 |
| Forward P/E | 28.4× | 11.4× | 4th most expensive of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Lushang Freda Pharmaceutical 600223.SS | China | $781M | -20% | +2% | 4% | 28.4× | n/a | n/a |
| Shenzhen Tellus 000025.SZ | China | $781M | -15% | -60% | 21% | n/a | n/a | n/a |
| Shenzhen New Nanshan Holding (Group) 002314.SZ | China | $784M | -16% | -55% | -36% | n/a | n/a | n/a |
| Archicom ARH.WA | Poland | $771M | -1% | +70% | 16% | 7.6× | n/a | n/a |
| Bright Real Estate 600708.SS | China | $769M | -37% | -54% | -82% | n/a | n/a | n/a |
| FastPartner FPAR-A.ST | Sweden | $767M | -13% | -2% | 66% | 11.4× | n/a | n/a |
| Guanghui Logistics 600603.SS | China | $767M | -20% | -24% | 13% | n/a | n/a | n/a |
| Robyg ROB.WA | Poland | $763M | n/a | +63% | 15% | n/a | n/a | n/a |
| New World Development 0017.HK | Hong Kong | $760M | -71% | +10% | -8% | n/a | n/a | n/a |
| Metro Land 600683.SS | China | $754M | -58% | +1,029% | -10% | n/a | n/a | n/a |
| K. Wah International 0173.HK | Hong Kong | $754M | -17% | -17% | 0% | 62.5× | n/a | n/a |
| Jm AB JM.ST | Sweden | $811M | +10% | -14% | 1% | 34.7× | n/a | n/a |
| PEXA PXA.AX | Australia | $813M | -42% | +3% | 13% | 44.1× | n/a | n/a |
| Wing Tai W05.SI | Singapore | $815M | -10% | +168% | 6% | n/a | n/a | n/a |
| Embassy Developments EMBDL.NS | India | $745M | -26% | -60% | -48% | n/a | n/a | n/a |
| Zhuhai Huafa Properties 600325.SS | China | $744M | -44% | -18% | -16% | n/a | n/a | n/a |
| Dios Fastigheter DIOS.ST | Sweden | $821M | -12% | +1% | 66% | 8.9× | n/a | n/a |
| United Overseas Australia UOS.AX | Australia | $740M | -11% | +13% | 37% | n/a | n/a | n/a |
| Sunac China 1918.HK | Hong Kong | $827M | -67% | -29% | -27% | n/a | n/a | n/a |
| Morguard MRC.TO | Canada | $830M | -7% | -1% | 53% | 3.8× | n/a | n/a |
| NIPPON KANZAI 9347.T | Japan | $733M | +10% | +7% | 6% | n/a | n/a | n/a |